



**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
CORE PHARMACY & THERAPEUTICS COMMITTEE**

August 31st, 2017

TO: DHS Core P&T Committee
MHLA Clinics

FROM: Jeffrey Guterman, M.D.
Shane D'Souza, Pharm.D.
Chairs, DHS Core Pharmacy and Therapeutics Committee

RE: August 2017 DHS Core Formulary Decisions

MY HEALTH LA FORMULARY

New Drug Additions

Drug Product	Comments
Imiquimod 5% cream	Added to MHLA 340B Formulary (Aldara® brand only)
Inhalation Spacers	Added to MHLA Formulary with restriction of 2 spacers per year for rescue inhalers and 1 spacer per year for control medications
Sodium Polystyrene Sulfonate (Kionex®) suspension	Added to MHLA 340B Formulary (Kionex® brand only)
Ranitidine 150mg tablets	Added to MHLA OTC2 formulary, Maximum of 180 tablets within any 90-day period
Buprenorphine 2mg, 8mg sublingual tablets	Added to MHLA 340B Formulary. Restricted to pharmacy only. Restricted to the treatment of opioid addiction by providers with a DATA 2000 waiver, or restricted to treatment of chronic pain in patient with a history of opioid dependence by providers with a DATA 2000 waiver. Maximum of 120 dosage units and a 30 day supply per dispensing
Buprenorphine-Naloxone 2mg-0.5mg, 8mg-2mg sublingual tablets	Added to MHLA 340B Formulary. Restricted to pharmacy only. Restricted to the treatment of opioid addiction by providers with a DATA 2000 waiver, or restricted to treatment of chronic pain in patient with a history of opioid dependence by providers with a DATA 2000 waiver. Maximum of 120 dosage units and a 30 day supply per dispensing

Formulary Changes

Drug Product	Comments
Ferrous Sulfate 325mg tablets	Maximum of 270 tablets within any 90-day period
Docusate Sodium 100mg capsule	Maximum of 270 Capsules within any 90-day period

Drug Deletion

Drug Product	Comments
Neomycin-Polymyxin-Hydrocortisone 0.35%/10000U/1%/mL ophthalmic suspension	Alternatives available on the MHLA Formulary (i.e., Dexamethasone-Neomycin-Polymyxin ophthalmic suspension, etc.)
Ofloxacin 0.3% Otic solution	Alternatives available on the MHLA Formulary (i.e., Ofloxacin 0.3% ophthalmic)

Formulary Requests Not Approved

Drug Product	Comments
Sucralfate (Carafate®) tablet	Alternatives available on the MHLA Formulary
Ciclopirox (Penlac®) topical solution	Alternatives available on the MHLA Formulary

This document contains confidential information intended for Los Angeles County Health Professionals and employees only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.